“South Africa’s health department has reported that over 31,000 people have already received the new six-monthly HIV prevention injection, lenacapavir, since its rollout began in June 2026. The data highlights strong uptake, particularly in Gauteng and KwaZulu-Natal, but also raises questions about equitable access and long-term supply.”
On 5 June 2026, South Africa embarked on one of the most ambitious public health rollouts in its history: the introduction of lenacapavir (LEN), a twice-yearly HIV prevention injection. This innovation, hailed as a potential game-changer in the fight against HIV/AIDS, has already reached more than 31,000 people in just six weeks. The rollout data, presented at the International AIDS Conference in Rio de Janeiro, provides a first glimpse into how South Africans are responding to this new option—and what challenges lie ahead.
Uptake and Distribution
- Total users in South Africa: 31,297 (out of ~60,000 across Africa).
- Clinic coverage: 360 government clinics (about 8% of public clinics).
- Provincial concentration: Gauteng (129 clinics) and KwaZulu-Natal (94 clinics) account for two-thirds of users.
- Preference: 98.5% of HIV-negative individuals offered a choice between daily pills and LEN chose the injection.
This overwhelming preference suggests that convenience is a decisive factor. For many, the burden of daily pill adherence has long been a barrier to effective HIV prevention. LEN’s twice-yearly schedule removes this obstacle, offering a discreet, long-acting solution.
Public Perception and Hesitancy
Health Minister Aaron Motsoaledi acknowledged initial concerns about vaccine hesitancy, especially after the COVID-19 pandemic. Some South Africans feared LEN might be a vaccine rather than a preventive treatment. However, uptake data shows these fears have largely been overcome, with strong acceptance across diverse communities.
Equity and Access Challenges
Despite the promising numbers, rollout data reveals disparities:
- Urban bias: Gauteng and KwaZulu-Natal dominate uptake, while rural provinces lag behind.
- Clinic availability: Only 8% of public clinics currently offer LEN, limiting access for many.
- Supply concerns: South Africa relies on donated doses, raising questions about sustainability until cheaper generics become available.
Broader Context in HIV Prevention
South Africa’s rollout comes amid global excitement about new HIV prevention tools. Alongside LEN, researchers are testing monthly pills (alimatravir) and even yearly injections, offering more options for different preferences. The key lesson: choice matters. By expanding the menu of prevention methods, health systems can better meet diverse needs.
Implications for Public Health
- Reduced infections: With ~140,000 new HIV infections annually in South Africa, LEN could significantly cut transmission rates.
- Adherence breakthrough: Twice-yearly dosing addresses one of the biggest challenges in HIV prevention—consistent adherence.
- Industrial opportunity: Local production of generics could strengthen Africa’s pharmaceutical sector and reduce costs.
Expert Perspectives
- Linda-Gail Bekker (South African HIV researcher): LEN is a “game-changer” but must be complemented by other options like monthly pills for those who dislike injections.
- Mitchell Warren (Avac): Generic licensing for alimatravir is a bold move that could accelerate access, but LEN’s rollout already demonstrates the power of innovation in prevention.
Conclusion
South Africa’s first six weeks of LEN rollout mark a historic milestone in HIV prevention. The data shows strong demand, high acceptance, and clear potential to reshape the country’s fight against HIV/AIDS. Yet challenges remain: ensuring equitable access, securing sustainable supply, and integrating LEN into a broader prevention strategy that includes pills and other options.
If South Africa can overcome these hurdles, LEN may not only reduce infections but also redefine how public health systems deliver prevention—making the dream of ending AIDS in Africa closer to reality.
